Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices 10229 

antibody and its respective epitope has 

been characterized at the atomic-level. 

Applications: 

1. Immunogens that elicit immune 

responses to HIV–1. 

2. Efficient development of vaccines 

against HIV–1. 

3. Screening tool to isolate antibodies 

with activities similar to identified 

template antibody. 

Inventors: Peter D. Kwong et al. 

(NIAID) 

Publications: 

1. G Ofek, W Schief, J Guenaga, et al. 

Epitope-transplant scaffolds: Automated 

design, structural analysis, and 

antigenic characteristics. Manuscript in 

preparation (2007). 

2. T Zhou, L Xu, B Dey, AJ Hessell, 

DV Ryk, SH Xiang, X Yang, MY Zhang, 

MB Zwick, J Arthos, DR Burton, DS 

Dimitrov, J Sodroski, R Wyatt, GJ Nabel, 

PD Kwong. Structural definition of a 

conserved neutralization epitope on 

HIV–1 gp120. Nature. 2007 Feb 

15;445(7129):732–737. 

3. DC Douek, PD Kwong, GJ Nabel. 

The rational design of an AIDS vaccine. 

Cell. 2006 Feb 24;124(4):677–681. 

4. G Ofek, M Tang, A Sambor, H 

Katinger, JR Mascola, R Wyatt, PD 

Kwong. Structure and mechanistic 

analysis of the anti-HIV–1 antibody 2F5 

in complex with its gp41 epitope. J 

Virol. 2004 Oct;78(19):10724–10737. 

Patent Status: 

1. PCT Application No. PCT/US2005/ 

016633 filed 13 May 2005, which 

published as WO 2005/111079 on 24 

Nov 2005 (HHS Reference No. E–218–

2004/0–PCT–02), and National Stage 

filed in the U.S. on 26 Nov 2006 (HHS 

Reference No. E–218–2004/0–US–03), 

entitled ‘‘HIV Vaccine Immunogens and 

Immunization Strategies to Elicit 

Broadly-Neutralizing Anti-HIV–1 

Antibodies Against the Membrane 

Proximal of HIV gp41’’. 

2. PCT Application No. PCT/US2006/ 

034681 filed 06 Sep 2006 (HHS 

Reference No. E–324–2005/3–PCT–01), 

entitled ‘‘Conformationally Stabilized 

HIV Envelope Immunogens and 

Triggering HIV-1 Envelope to Reveal 

Cryptic V3-Loop Epitopes’’

3. PCT Application No. PCT/US2006/ 

034882 filed 06 Sep 2006 (HHS 

Reference No. E–280–2006/1–PCT–01), 

entitled ‘‘HIV gp120 Crystal Structure 

and Its Use to Identify Immunogens’’

4. U.S. Provisional Application No. 

60/840,119 filed 25 Aug 2006 (HHS 

Reference No. E–302–2006/0–US–01), 

entitled ‘‘Epitope-Transplant Scaffolds 

and Their Use’’

Licensing Availability: Available for 

non-exclusive or exclusive licensing. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov 

CCR5-Specific Human Monoclonal 

Antibodies 

Description of Technology: The 

subject invention provides the 

composition claims related to anti-CCR5 

monoclonal antibodies, their fusion 

protein, conjugates, derivatives, or 

fragments, DNA sequences encoding 

such antibodies, host cells containing 

such DNA sequences, as well as the 

methods to produce them 

recombinantly and their 

pharmacological composition. 

It has been demonstrated that the HIV 

co-receptor CCR5 plays an important 

role in virus entry. The subject 

antibodies exhibited neutralization 

activity against HIV–1 infection by 

binding to cell associated CCR5 in vitro. 

Moreover, subject antibodies have 

potentially lower immunogenicity and 

toxicity, because they are fully human 

antibodies. Therefore, subject anti-CCR5 

antibodies have a potential as a 

therapeutic and/or prophylactic in 

combination with other HIV–1 

neutralizing antibodies and antiretroviral drugs. 

Applications: HIV treatment and 

prevention. 

Development Status: In vitro data is 

available at this time. 

Inventors: Dimiter S. Dimitrov and 

Mei-Yun Zhang (NCI). 

Related Publications: 

1. C Pastori et al. Long-lasting CCR5 

internalization by antibodies in a subset 

of long-term nonprogressors: A possible 

protective effect against disease 

progression. Blood. 2006 Jun 

15;107(12):4825–4833. 

2. MY Zhang, B Vu, CC Huang, I 

Sidirov, V Choudhly, PD Kwong, DS 

Dimitrov. Identification of human 

monoclonal antibodies specific for 

CCR5 from an antibody library derived 

from HIV-infected long-term nonprogressors. Retrovirology. 2006 Dec 

21;3 Suppl 1:S61. 

3. DS Dimitrov. Virus entry: 

molecular mechanisms and biomedical 

applications. Nat Rev Microbiol. 2004 

Feb;2(2):109–122. 

Patent Status: U.S. Provisional 

Application No. 60/859,401 filed 15 

Nov 2006 (HHS Reference No. E–297–

2006/0–US–01) 

Licensing Availability: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Sally Hu, Ph.D.; 

301/435–5606; HuS@mail.nih.gov. 

Collaborative Research Opportunity: 

The NCI CCR Nanobiology Program is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

monoclonal antibodies. Please contact 

John D. Hewes, Ph.D. at 301–435–3121 

or hewesj@mail.nih.gov for more 

information. 

Dated: February 28, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer 

National Institutes of Health. 

[FR Doc. E7–3959 Filed 3–6–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Advisory Committee on Research on 

Women’s Health. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Advisory Committee 

on Research on Women’s Health. 

Date: March 29–30, 2007. 

Time: March 29, 2007, 9 a.m. to 5 p.m. 

Agenda: Provide advice to the Office of 

Research on Women’s Health (ORWH) on 

appropriate research activities with respect to 

women’s health and related studies to be 

undertaken by the National Research 

Institutes; to provide recommendations 

regarding ORWH activities; to meet the 

mandates of the office; and for discussion of 

scientific issues. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6C/10, 

Bethesda, MD 20892. 

Time: March 30, 2007, 9 a.m. to 1 p.m. 

Agenda: Same as above. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6C/10, 

Bethesda, MD 20892. 

Contact Person: Joyce Rudick, Director, 

Programs & Management, Office of Research 

on Women’s Health, Office of the Director, 

National Institutes of Health, Building 1, 

Room 201, Bethesda, MD 20892, 301/402–

1770. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www4.od.nih.gov/orwh/, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 


sroberts on PROD1PC70 with NOTICES
10230 Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiancy Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: February 28, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1041 Filed 3–6–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language itnerpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group. 

Date: March 29–30, 2007. 

Time: March 29, 2007, 8:45 a.m. to 5:30 

p.m. 

Agenda: 1. Approval of Minutes; 2. Report 

from Dr. John E. Niederhuber, NCI Director; 

3. Reports on NCI Budget; Legislative 

Activity; NCI Scientific Initiatives by NCI 

Staff; Reports of DCLG Working Group and 

member activity; 4. Report on NCI Listens 

and Learns Evaluations; 5. Public Comment. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conf. Rm. 6, 

Bethesda, MD 20892. 

Time: March 30, 2007, 2:00 p.m. to 3:30 

p.m. 

Agenda: Action Items and Conclusion. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conf. Rm 6, 

Bethesda, MD 20892. 

Contact Person: Barbara Guest, Executive 

Secretary, Office of Liaison Activities, 

National Cancer Institute, National Institutes 

of Health, 6116 Executive Blvd., Room 2202, 

Bethesda, MD 20892–8324, 301–496–0307, 

guestb@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has institute 

stringent procedures for entrance onto the 

NIH campus. All visitor vehicles, including 

taxicabs, hotel, and airport shuttles will be 

inspected before being allowed on campus. 

Visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 28, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1035 Filed 3–6–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Special Emphasis Panel, 

February 15, 2007, 12 p.m. to February 

15, 2007, 6 p.m., National Institutes of 

Health, 6116 Executive Boulevard, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

January 30, 2007, 72FR4276. 

The meeting notice is changed to 

reflect the date change from February 

15, 2007 to March 7, 2007. The meeting 

is closed to the public. 

Dated: February 28, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1036 Filed 3–6–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel, Mechanisms of 

Immune Modulation. 

Date: March 22–23, 2007. 

Time: 4 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hills 

Road, Bethesda, MD 20814. 

Contact Person: Martina Schmidt, PhD, 

Scientific Review Administrator, Office of 

Scientific Review, National Center for 

Complementary and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, 301–594–3456, 

schmidma@mail.nih.gov. 

Dated: February 28, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1039 Filed 3–6–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEATLH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center on Minority Health and 

Health Disparities; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center on 

Minority Health and Health Disparities 

Special Emphasis Panel, Loan Repayment 


sroberts on PROD1PC70 with NOTICES